BioSpace News Archive

The antiseptic and disinfectant market survey offers insights into chief growth drivers and restrains impacting the overall growth trajectory.

MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces the enrollment of the first patient in Europe in its pivotal Phase III clinical study of PXT3003 in Charcot-Marie-Tooth disease type 1A.

Daré Bioscience, Inc. announced that it entered into a Cooperative Research and Development Agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, for the pivotal Phase 3 study of Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive currently in clinical development for the prevention of pregnancy.

Three oncology practices with a combined total of ten physicians have recently joined The Center for Cancer and Blood Disorders, the growing North Texas independent oncology practice, an affiliate of OneOncology, announced.

Alzamend Neuro®, Inc. announced that its Chairman of the Board, William B. Horne, its CEO, Stephan Jackman and its Founder and Chairman Emeritus, Milton “Todd” Ault, III, will join members of the Company’s management, Board of Directors and founding stockholders to ring the opening bell at the Nasdaq stock exchange on Monday, July 12, 2021 at 9:30 am ET at the Nasdaq MarketSite at Times Square.

Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Anna Quattropani, PhD, as Chief Discovery Officer, effective immediately.

Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea together with other members of the Atea management team, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 12:00 p.m. ET.

FibroGen, Inc. announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.

Clinical Laserthermia Systems AB today announced it has received approval from Health Canada for its updated sterilization documentation as well as an acceptance for its new sterilization supplier, ROSE GmbH.